{"success":true,"data":{"pressRelease":{"id":"31561","rtpr_id":"nGNX5ZvzlJ","ticker":"HIMS","exchange":"NYSE","all_tickers":["HIMS","LLY","PFE","BPC","NOVOB"],"title":"Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates","author":"Globe Newswire","published_at":"2026-05-12T13:00:00.682Z","article_body":"NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary\n-- Investor interest in the next-generation wellness market is picking up fast\nas peptide-based health and performance products become more mainstream. More\nconsumers are looking for wellness solutions that go beyond traditional\nsupplements — products designed to support energy, recovery, metabolism,\nhealthy aging, fitness, and overall well-being. As people become more focused\non taking control of their health earlier in life, demand for science-backed\npeptide products continues to grow, creating major opportunities for companies\ndeveloping high-quality formulations and modern wellness platforms. Investors\nlooking for emerging opportunities in the fast-growing wellness and\nbiotechnology sectors should keep a close eye on the following companies as\nthey continue to advance operations, expand market presence, and pursue new\ngrowth catalysts: The Precision Peptide Company Inc. (OTCQB: PNGAF) (CSE:\nBPC), Pfizer Inc. (NYSE: PFE), Novo Nordisk A/S (NYSE: NVO), Hims & Hers\nHealth, Inc. (NYSE: HIMS), Eli Lilly and Company (NYSE: LLY).\n\nThe growth potential in the peptide and metabolic health market is getting a\nlot of attention for good reason. Industry reports project\n(https://www.globenewswire.com/Tracker?data=egdqX9fn5uTUw6kZqmR_OCn2tzwAjwDdEulemy0zPGj2se5UlGKCb1wnG_4RVjTXMfks45GytoD7tmygia5nQPa-JswspIw4vGR_CZTSIP1Ja1sGhnaS-MW77-Apqz6lkly-MPPrLZihmuO-qrraCCBrLO_anOfuj15PKIB4k2o=)\nthe global peptide therapeutics market could grow from around $117 billion in\n2024 to more than $260 billion by 2030, with some forecasts pushing the market\nclose to $300 billion over the next several years. A big part of that growth\nis coming from rising interest in weight management, anti-aging solutions,\npreventative health, and personalized wellness programs. The popularity of\nGLP-1 therapies and other peptide technologies has also helped bring more\nawareness to the space, while analysts believe\n(https://www.globenewswire.com/Tracker?data=_4DFeab-krsEyiRwLeRw4tzUrL0pLRfJOKefhFFQYKYkOPyE5awI2WJCw3MEhdVwX1yMfYcQIo0womD1SaLS__fS6LOm_C1G9J1lpzbLJGos9F9nANb8I3vzOXm8CRxotBSqIAZj0Iw23QS-iMUYcnKokwVyaolVx3LrE3XKLuQMineyXCZrIKckVH6B4D8dy5d_mlSjyv-3o8nVB9ldaEJuOq431VeMlN4Yco52rfU=)\nthe obesity and metabolic health market alone could surpass $100 billion by\n2030.\n\nFor investors, companies focused on premium peptide wellness products offer\nexposure to one of the fastest-growing trends in healthcare and wellness\ntoday. Consumers are spending more money on products that help them feel\nbetter, recover faster, stay healthier longer, and improve overall quality of\nlife. Wellness platforms that combine innovative peptide products with\ndirect-to-consumer sales, digital engagement, and recurring revenue models are\nin a strong position to scale as the market continues expanding. With growing\nawareness and strong long-term demand trends, many investors see the peptide\nwellness sector as a high-growth opportunity still in the early stages of\ndevelopment.\n\nTHE PRECISION PEPTIDE COMPANY INC. (OTCQB:PNGAF) (CSE:BPC) ANNOUNCES EXCLUSIVE\nSTRATEGIC MARKETING PARTNERSHIP WITH MIXED MARTIAL ARTS GROUP LIMITED - The\nPrecision Peptide Company\n(https://www.globenewswire.com/Tracker?data=k8KTroqAedCdaiomgno5mEpVS82i7U02JWr9TEQMd2LhC_yuY3NL1v14LnOTEoXb-flE6HL2hS61evndK7kXalHVyHuP6GCiFFfberxPdigCcB4puWVzyva0vT_JFE4r)\n(the \"Company\" or \"BPC\"), a publicly traded wellness company focused on\nadvanced peptide formulations and delivery systems, today announces that it\nhas entered into an Exclusive Strategic Marketing Agreement (the \"Strategic\nMarketing Agreement\") dated May 8, 2026 with Mixed Martial Arts Group Limited\n(\"MMA\"), a New South Wales, Australia-based company.\n\nUnder the Strategic Marketing Agreement, the parties have entered into an\nexclusive partnership for the purposes of marketing and selling the Company's\npeptide products to MMA's subscriber base. MMA operates one of the world’s\nlargest digitally connected combat sports ecosystems, with over 5 million\nsocial media followers, with approximately 530,000 user profiles, more than\n75,000 active students and over 800 verified gyms globally and will market the\nCompany's products to all individuals and entities subscribed to MMA's\nplatform as of the effective date and throughout the term of the Strategic\nMarketing Agreement.\n\nPursuant to the Strategic Marketing Agreement, the Company will pay MMA a\nshare of net revenue derived exclusively from MMA-sourced sales. During the\nfirst twelve (12) months following the effective date, net revenue from\nMMA-sourced sales will be split equally between the parties on a 50%/50%\nbasis. Commencing in the thirteenth (13th) month following the effective date\nand for the remainder of the term, net revenue from MMA-sourced sales will be\ndistributed 75% to the Company and 25% to MMA.\n\nThe Strategic Marketing Agreement commences on May 8, 2026 and continues until\nterminated, with either party having the right to terminate for any reason\nupon no less than thirty (30) days' prior written notice. For a period of\ntwelve (12) months following termination or expiration of the Strategic\nMarketing Agreement, the Company will continue to account for and pay MMA's\napplicable profit share on sales to customers referred by MMA during the term.\n\nAll peptide products sold under the Strategic Marketing Agreement will be\nmanufactured in the United States of America and will comply with all\napplicable U.S. regulatory requirements and standards, including those set by\nthe U.S. Food and Drug Administration and any other applicable regulatory\nauthority. Continued… Read this full release and additional news for\nPrecision Peptide Company by visiting:\nhttps://research.quotemedia.com/equity/home/news?symbol=BPC:CNX\n\nRecent News, Strategic Developments, and Growth Catalysts Shaping the Biotech\nand Pharmaceutical Sectors Include:\n\nPfizer Inc. (NYSE: PFE) recently announced\n(https://www.globenewswire.com/Tracker?data=sTg1BzgFkfEm94cAzQRH4SnXnU4Ir2hlodetFnYcnc07XIQSQ5-DMxscxfyycwZL0iTV2qcRsZZWwJIVzNhbeJfbxFmwMoH2wpjp5gEAPkiiL9s9TNSm2NhdFvPqjpFVJd-SXN_ruuHE3blxDkOaLq2J_OSXD5PQ-DZkoKtjDx3hE8Z5GlBo086J2RtMQkFwDOQQ-T4qLqGHlKlSFshFjQ==)\npositive topline results from the Phase 2b VESPER-3 study investigating\nmonthly maintenance dosing of its fully-biased, ultra-long-acting, injectable\nGLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or\noverweight without type 2 diabetes. The study had two objectives:\n\n(1) to demonstrate PF’3944 could achieve continued weight loss when\nswitching from weekly to monthly subcutaneous injections and maintain its\nefficacy while reducing the dosing frequency four-fold; and\n\n(2) to demonstrate PF’3944 could switch to a four-fold equivalent monthly\ndose while maintaining a well-tolerated and favorable safety profile.\n\nAmazon Pharmacy, a full-service digital pharmacy that delivers medications\ndirectly to customers' homes, is expanding access to Novo Nordisk A/S (NYSE:\nNVO)'s Ozempic(®) pill, the only FDA-approved oral GLP-1 medication to treat\ntype 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and\npickup within minutes through in-office kiosk locations soon, addressing a\ncritical access gap for the more than 36 million Americans living with type 2\ndiabetes.\n\nCustomers with an Ozempic pill prescription can order through Amazon Pharmacy,\nsee real-time availability in their area, view transparent pricing and receive\nfast delivery directly to their door nationwide, regardless of Prime\nmembership. With insurance, pricing starts as low as $25 per month. For\ncash-pay customers, pricing begins at $149 per month with\nmanufacturer-sponsored savings offers applied automatically before checkout.\n\nHims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness\nplatform, announced\n(https://www.globenewswire.com/Tracker?data=sTg1BzgFkfEm94cAzQRH4fVyufmJQfEWMa8_8iSfdbUx9Jf2I5RmEWR8DCuklPjvk-sew74NDx8CB_I1bXIFhl1yB43DWOsnWlJWxkfz2SJjPx7zioNNu2aHt2rBfWVXAAjb69O2SNczQxIN7IY5QZpLMrA-v0qcEe8nkyVrqNLB6Zjrew2mmFkn_Yp1co9GW5VEAST6M2dbYk_k_URcowGVQRQRqmmmPqgTGeMsbX4=)\nfinancial results for the first quarter ended March 31, 2026. Moving forward,\nthe Company plans to transition to an annual rather than quarterly shareholder\nletter and will continue to provide regular updates through a quarterly\nearnings call, earnings release, and supplemental materials.\n\n“2026 is a defining year for Hims & Hers. We’re not just growing, we’re\npulling away from the field on our path to becoming the world’s largest\nconsumer health platform,” said Andrew Dudum, co-founder and CEO. “As we\nexit the first quarter, our domestic business is accelerating, we’re\nexpanding into new categories and countries, and more people than ever are\nrelying on us for access to personal, data-driven care. We’re investing with\nconviction in comprehensive diagnostics and a technology infrastructure built\nto make every interaction smarter than the last. The demand for a simpler,\nmore personal path to feeling great has never been stronger, and Hims & Hers\nis increasingly the answer.”\n\n“In the first quarter, we made a strategic pivot that expanded our\nassortment of branded GLP-1 products, and early demand signals show our\nconsumer reach broadening meaningfully,\" said Yemi Okupe, Chief Financial\nOfficer. \"With nearly 2.6 million subscribers across a diverse breadth of\nspecialties, we have the scale to invest in technology and operations to\nleverage our closed-loop ecosystem. This will allow us to elevate the\nsubscriber experience and positions us to achieve an industry-leading cost\nstructure. We expect growth to accelerate from here, and have high conviction\nin our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in\nAdjusted EBITDA.”\n\nEli Lilly and Company (NYSE: LLY) announced\n(https://www.globenewswire.com/Tracker?data=sTg1BzgFkfEm94cAzQRH4cdG7ApETZmfL0DmObzYBE_YWuMQHFwA6US9DwwCyEHYkJjbq16PaXQKBbCukbknwfJoQ-8TgOp0kZ0W7kxP9EZi1NHxJf4PX86piE6Ag10wpFE3r1IIWskel-75wI6v83vKSPh2RjYaxOfLUAnORq9gP8IQ5NKhw8GUKEUb_DT0G47RwovVOGc-Q_OCmJrsKcXbUQEkpeH9Q2arIxSN0sQ=)\nan additional $4.5 billion investment across two of its three Lebanon\nsites—bringing the company's total Indiana capital expansion commitments\nsince 2020 to more than $21 billion. Lilly's evolving pipeline, as well as\nanticipated demand for its medicines, prompted this additional commitment. The\ninvestment will incorporate new process designs and technologies at Lilly\nLebanon API, one of the company's future active pharmaceutical ingredient\nsites, as well as Lilly Lebanon Advanced Therapies, its first dedicated\ngenetic medicine manufacturing facility opening today.\n\nLilly Lebanon Advanced Therapies is designed to support both clinical and\ncommercial production of advanced therapies that target disease at the genetic\nlevel and will include a full spectrum of genetic medicine modalities from\nresearch-stage development through large-scale commercial supply. Designing\nand building for these modalities required developing new manufacturing\nprocesses without established commercial precedent. This facility is the first\nof three planned sites on the Lebanon campus, which will also include Lilly\nLebanon API and the Lilly Medicine Foundry.\n\nDISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news\ndissemination service provider, which disseminates electronic information\nthrough multiple online media channels. MNU is NOT affiliated in any manner\nwith any company mentioned herein. MNU and its affiliated companies are a news\ndissemination solutions provider and are NOT a registered\nbroker/dealer/analyst/adviser, holds no investment licenses and may NOT sell,\noffer to sell or offer to buy any security. MNU’S market updates, news\nalerts and corporate profiles are NOT a solicitation or recommendation to buy,\nsell or hold securities. The material in this release is intended to be\nstrictly informational and is NEVER to be construed or interpreted as research\nmaterial. All readers are strongly urged to perform research and due diligence\non their own and consult a licensed financial professional before considering\nany level of investing in stocks. All material included herein is republished\ncontent and details which were previously disseminated by the companies\nmentioned in this release. MNU is not liable for any investment decisions by\nits readers or subscribers. Investors are cautioned that they may lose all or\na portion of their investment when investing in stocks. This press release\nwas distributed on behalf of The Precision Peptide Company. For current\nservices performed MNU was compensated forty-six hundred dollars for news\ncoverage of the current press releases issued by The Precision Peptide Company\nby a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN\nTHIS RELEASE.\n\nThis release contains \"forward-looking statements\" within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E the\nSecurities Exchange Act of 1934, as amended and such forward-looking\nstatements are made pursuant to the safe harbor provisions of the Private\nSecurities Litigation Reform Act of 1995. \"Forward-looking statements\"\ndescribe future expectations, plans, results, or strategies and are generally\npreceded by words such as \"may\", \"future\", \"plan\" or \"planned\", \"will\" or\n\"should\", \"expected,\" \"anticipates\", \"draft\", \"eventually\" or \"projected\". You\nare cautioned that such statements are subject to a multitude of risks and\nuncertainties that could cause future circumstances, events, or results to\ndiffer materially from those projected in the forward-looking statements,\nincluding the risks that actual results may differ materially from those\nprojected in the forward-looking statements as a result of various factors,\nand other risks identified in a company's annual report on Form 10-K or 10-KSB\nand other filings made by such company with the Securities and Exchange\nCommission. You should consider these factors in evaluating the\nforward-looking statements included herein, and not place undue reliance on\nsuch statements. The forward-looking statements in this release are made as of\nthe date hereof and MNU undertakes no obligation to update such statements.\n\nContact Information:\n\nMedia Contact email: editor@marketnewsupdates.com - +1(561)486-1799\n\nSOURCE: Market News Updates\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dbf64641-d61f-43e0-9ae8-0bf103e13852)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5ZvzlJ","title":"Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates","author":"Globe Newswire","ticker":"HIMS","created":"2026-05-12T13:00:00.682Z","tickers":["HIMS","LLY","PFE","BPC","NOVOB"],"exchange":"NYSE","article_body":"NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary\n-- Investor interest in the next-generation wellness market is picking up fast\nas peptide-based health and performance products become more mainstream. More\nconsumers are looking for wellness solutions that go beyond traditional\nsupplements — products designed to support energy, recovery, metabolism,\nhealthy aging, fitness, and overall well-being. As people become more focused\non taking control of their health earlier in life, demand for science-backed\npeptide products continues to grow, creating major opportunities for companies\ndeveloping high-quality formulations and modern wellness platforms. Investors\nlooking for emerging opportunities in the fast-growing wellness and\nbiotechnology sectors should keep a close eye on the following companies as\nthey continue to advance operations, expand market presence, and pursue new\ngrowth catalysts: The Precision Peptide Company Inc. (OTCQB: PNGAF) (CSE:\nBPC), Pfizer Inc. (NYSE: PFE), Novo Nordisk A/S (NYSE: NVO), Hims & Hers\nHealth, Inc. (NYSE: HIMS), Eli Lilly and Company (NYSE: LLY).\n\nThe growth potential in the peptide and metabolic health market is getting a\nlot of attention for good reason. Industry reports project\n(https://www.globenewswire.com/Tracker?data=egdqX9fn5uTUw6kZqmR_OCn2tzwAjwDdEulemy0zPGj2se5UlGKCb1wnG_4RVjTXMfks45GytoD7tmygia5nQPa-JswspIw4vGR_CZTSIP1Ja1sGhnaS-MW77-Apqz6lkly-MPPrLZihmuO-qrraCCBrLO_anOfuj15PKIB4k2o=)\nthe global peptide therapeutics market could grow from around $117 billion in\n2024 to more than $260 billion by 2030, with some forecasts pushing the market\nclose to $300 billion over the next several years. A big part of that growth\nis coming from rising interest in weight management, anti-aging solutions,\npreventative health, and personalized wellness programs. The popularity of\nGLP-1 therapies and other peptide technologies has also helped bring more\nawareness to the space, while analysts believe\n(https://www.globenewswire.com/Tracker?data=_4DFeab-krsEyiRwLeRw4tzUrL0pLRfJOKefhFFQYKYkOPyE5awI2WJCw3MEhdVwX1yMfYcQIo0womD1SaLS__fS6LOm_C1G9J1lpzbLJGos9F9nANb8I3vzOXm8CRxotBSqIAZj0Iw23QS-iMUYcnKokwVyaolVx3LrE3XKLuQMineyXCZrIKckVH6B4D8dy5d_mlSjyv-3o8nVB9ldaEJuOq431VeMlN4Yco52rfU=)\nthe obesity and metabolic health market alone could surpass $100 billion by\n2030.\n\nFor investors, companies focused on premium peptide wellness products offer\nexposure to one of the fastest-growing trends in healthcare and wellness\ntoday. Consumers are spending more money on products that help them feel\nbetter, recover faster, stay healthier longer, and improve overall quality of\nlife. Wellness platforms that combine innovative peptide products with\ndirect-to-consumer sales, digital engagement, and recurring revenue models are\nin a strong position to scale as the market continues expanding. With growing\nawareness and strong long-term demand trends, many investors see the peptide\nwellness sector as a high-growth opportunity still in the early stages of\ndevelopment.\n\nTHE PRECISION PEPTIDE COMPANY INC. (OTCQB:PNGAF) (CSE:BPC) ANNOUNCES EXCLUSIVE\nSTRATEGIC MARKETING PARTNERSHIP WITH MIXED MARTIAL ARTS GROUP LIMITED - The\nPrecision Peptide Company\n(https://www.globenewswire.com/Tracker?data=k8KTroqAedCdaiomgno5mEpVS82i7U02JWr9TEQMd2LhC_yuY3NL1v14LnOTEoXb-flE6HL2hS61evndK7kXalHVyHuP6GCiFFfberxPdigCcB4puWVzyva0vT_JFE4r)\n(the \"Company\" or \"BPC\"), a publicly traded wellness company focused on\nadvanced peptide formulations and delivery systems, today announces that it\nhas entered into an Exclusive Strategic Marketing Agreement (the \"Strategic\nMarketing Agreement\") dated May 8, 2026 with Mixed Martial Arts Group Limited\n(\"MMA\"), a New South Wales, Australia-based company.\n\nUnder the Strategic Marketing Agreement, the parties have entered into an\nexclusive partnership for the purposes of marketing and selling the Company's\npeptide products to MMA's subscriber base. MMA operates one of the world’s\nlargest digitally connected combat sports ecosystems, with over 5 million\nsocial media followers, with approximately 530,000 user profiles, more than\n75,000 active students and over 800 verified gyms globally and will market the\nCompany's products to all individuals and entities subscribed to MMA's\nplatform as of the effective date and throughout the term of the Strategic\nMarketing Agreement.\n\nPursuant to the Strategic Marketing Agreement, the Company will pay MMA a\nshare of net revenue derived exclusively from MMA-sourced sales. During the\nfirst twelve (12) months following the effective date, net revenue from\nMMA-sourced sales will be split equally between the parties on a 50%/50%\nbasis. Commencing in the thirteenth (13th) month following the effective date\nand for the remainder of the term, net revenue from MMA-sourced sales will be\ndistributed 75% to the Company and 25% to MMA.\n\nThe Strategic Marketing Agreement commences on May 8, 2026 and continues until\nterminated, with either party having the right to terminate for any reason\nupon no less than thirty (30) days' prior written notice. For a period of\ntwelve (12) months following termination or expiration of the Strategic\nMarketing Agreement, the Company will continue to account for and pay MMA's\napplicable profit share on sales to customers referred by MMA during the term.\n\nAll peptide products sold under the Strategic Marketing Agreement will be\nmanufactured in the United States of America and will comply with all\napplicable U.S. regulatory requirements and standards, including those set by\nthe U.S. Food and Drug Administration and any other applicable regulatory\nauthority. Continued… Read this full release and additional news for\nPrecision Peptide Company by visiting:\nhttps://research.quotemedia.com/equity/home/news?symbol=BPC:CNX\n\nRecent News, Strategic Developments, and Growth Catalysts Shaping the Biotech\nand Pharmaceutical Sectors Include:\n\nPfizer Inc. (NYSE: PFE) recently announced\n(https://www.globenewswire.com/Tracker?data=sTg1BzgFkfEm94cAzQRH4SnXnU4Ir2hlodetFnYcnc07XIQSQ5-DMxscxfyycwZL0iTV2qcRsZZWwJIVzNhbeJfbxFmwMoH2wpjp5gEAPkiiL9s9TNSm2NhdFvPqjpFVJd-SXN_ruuHE3blxDkOaLq2J_OSXD5PQ-DZkoKtjDx3hE8Z5GlBo086J2RtMQkFwDOQQ-T4qLqGHlKlSFshFjQ==)\npositive topline results from the Phase 2b VESPER-3 study investigating\nmonthly maintenance dosing of its fully-biased, ultra-long-acting, injectable\nGLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or\noverweight without type 2 diabetes. The study had two objectives:\n\n(1) to demonstrate PF’3944 could achieve continued weight loss when\nswitching from weekly to monthly subcutaneous injections and maintain its\nefficacy while reducing the dosing frequency four-fold; and\n\n(2) to demonstrate PF’3944 could switch to a four-fold equivalent monthly\ndose while maintaining a well-tolerated and favorable safety profile.\n\nAmazon Pharmacy, a full-service digital pharmacy that delivers medications\ndirectly to customers' homes, is expanding access to Novo Nordisk A/S (NYSE:\nNVO)'s Ozempic(®) pill, the only FDA-approved oral GLP-1 medication to treat\ntype 2 diabetes. Amazon Pharmacy will offer Same-Day prescription delivery and\npickup within minutes through in-office kiosk locations soon, addressing a\ncritical access gap for the more than 36 million Americans living with type 2\ndiabetes.\n\nCustomers with an Ozempic pill prescription can order through Amazon Pharmacy,\nsee real-time availability in their area, view transparent pricing and receive\nfast delivery directly to their door nationwide, regardless of Prime\nmembership. With insurance, pricing starts as low as $25 per month. For\ncash-pay customers, pricing begins at $149 per month with\nmanufacturer-sponsored savings offers applied automatically before checkout.\n\nHims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness\nplatform, announced\n(https://www.globenewswire.com/Tracker?data=sTg1BzgFkfEm94cAzQRH4fVyufmJQfEWMa8_8iSfdbUx9Jf2I5RmEWR8DCuklPjvk-sew74NDx8CB_I1bXIFhl1yB43DWOsnWlJWxkfz2SJjPx7zioNNu2aHt2rBfWVXAAjb69O2SNczQxIN7IY5QZpLMrA-v0qcEe8nkyVrqNLB6Zjrew2mmFkn_Yp1co9GW5VEAST6M2dbYk_k_URcowGVQRQRqmmmPqgTGeMsbX4=)\nfinancial results for the first quarter ended March 31, 2026. Moving forward,\nthe Company plans to transition to an annual rather than quarterly shareholder\nletter and will continue to provide regular updates through a quarterly\nearnings call, earnings release, and supplemental materials.\n\n“2026 is a defining year for Hims & Hers. We’re not just growing, we’re\npulling away from the field on our path to becoming the world’s largest\nconsumer health platform,” said Andrew Dudum, co-founder and CEO. “As we\nexit the first quarter, our domestic business is accelerating, we’re\nexpanding into new categories and countries, and more people than ever are\nrelying on us for access to personal, data-driven care. We’re investing with\nconviction in comprehensive diagnostics and a technology infrastructure built\nto make every interaction smarter than the last. The demand for a simpler,\nmore personal path to feeling great has never been stronger, and Hims & Hers\nis increasingly the answer.”\n\n“In the first quarter, we made a strategic pivot that expanded our\nassortment of branded GLP-1 products, and early demand signals show our\nconsumer reach broadening meaningfully,\" said Yemi Okupe, Chief Financial\nOfficer. \"With nearly 2.6 million subscribers across a diverse breadth of\nspecialties, we have the scale to invest in technology and operations to\nleverage our closed-loop ecosystem. This will allow us to elevate the\nsubscriber experience and positions us to achieve an industry-leading cost\nstructure. We expect growth to accelerate from here, and have high conviction\nin our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in\nAdjusted EBITDA.”\n\nEli Lilly and Company (NYSE: LLY) announced\n(https://www.globenewswire.com/Tracker?data=sTg1BzgFkfEm94cAzQRH4cdG7ApETZmfL0DmObzYBE_YWuMQHFwA6US9DwwCyEHYkJjbq16PaXQKBbCukbknwfJoQ-8TgOp0kZ0W7kxP9EZi1NHxJf4PX86piE6Ag10wpFE3r1IIWskel-75wI6v83vKSPh2RjYaxOfLUAnORq9gP8IQ5NKhw8GUKEUb_DT0G47RwovVOGc-Q_OCmJrsKcXbUQEkpeH9Q2arIxSN0sQ=)\nan additional $4.5 billion investment across two of its three Lebanon\nsites—bringing the company's total Indiana capital expansion commitments\nsince 2020 to more than $21 billion. Lilly's evolving pipeline, as well as\nanticipated demand for its medicines, prompted this additional commitment. The\ninvestment will incorporate new process designs and technologies at Lilly\nLebanon API, one of the company's future active pharmaceutical ingredient\nsites, as well as Lilly Lebanon Advanced Therapies, its first dedicated\ngenetic medicine manufacturing facility opening today.\n\nLilly Lebanon Advanced Therapies is designed to support both clinical and\ncommercial production of advanced therapies that target disease at the genetic\nlevel and will include a full spectrum of genetic medicine modalities from\nresearch-stage development through large-scale commercial supply. Designing\nand building for these modalities required developing new manufacturing\nprocesses without established commercial precedent. This facility is the first\nof three planned sites on the Lebanon campus, which will also include Lilly\nLebanon API and the Lilly Medicine Foundry.\n\nDISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news\ndissemination service provider, which disseminates electronic information\nthrough multiple online media channels. MNU is NOT affiliated in any manner\nwith any company mentioned herein. MNU and its affiliated companies are a news\ndissemination solutions provider and are NOT a registered\nbroker/dealer/analyst/adviser, holds no investment licenses and may NOT sell,\noffer to sell or offer to buy any security. MNU’S market updates, news\nalerts and corporate profiles are NOT a solicitation or recommendation to buy,\nsell or hold securities. The material in this release is intended to be\nstrictly informational and is NEVER to be construed or interpreted as research\nmaterial. All readers are strongly urged to perform research and due diligence\non their own and consult a licensed financial professional before considering\nany level of investing in stocks. All material included herein is republished\ncontent and details which were previously disseminated by the companies\nmentioned in this release. MNU is not liable for any investment decisions by\nits readers or subscribers. Investors are cautioned that they may lose all or\na portion of their investment when investing in stocks. This press release\nwas distributed on behalf of The Precision Peptide Company. For current\nservices performed MNU was compensated forty-six hundred dollars for news\ncoverage of the current press releases issued by The Precision Peptide Company\nby a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN\nTHIS RELEASE.\n\nThis release contains \"forward-looking statements\" within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E the\nSecurities Exchange Act of 1934, as amended and such forward-looking\nstatements are made pursuant to the safe harbor provisions of the Private\nSecurities Litigation Reform Act of 1995. \"Forward-looking statements\"\ndescribe future expectations, plans, results, or strategies and are generally\npreceded by words such as \"may\", \"future\", \"plan\" or \"planned\", \"will\" or\n\"should\", \"expected,\" \"anticipates\", \"draft\", \"eventually\" or \"projected\". You\nare cautioned that such statements are subject to a multitude of risks and\nuncertainties that could cause future circumstances, events, or results to\ndiffer materially from those projected in the forward-looking statements,\nincluding the risks that actual results may differ materially from those\nprojected in the forward-looking statements as a result of various factors,\nand other risks identified in a company's annual report on Form 10-K or 10-KSB\nand other filings made by such company with the Securities and Exchange\nCommission. You should consider these factors in evaluating the\nforward-looking statements included herein, and not place undue reliance on\nsuch statements. The forward-looking statements in this release are made as of\nthe date hereof and MNU undertakes no obligation to update such statements.\n\nContact Information:\n\nMedia Contact email: editor@marketnewsupdates.com - +1(561)486-1799\n\nSOURCE: Market News Updates\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dbf64641-d61f-43e0-9ae8-0bf103e13852)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-12T13:00:00.794007017Z","server_sent_at_ms":1778590800794},"received_at":"2026-05-12T13:00:00.890Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}